1988.-Endothelin is a recently discovered vasoconstrictor peptide that is synthesized in certain vascular endothelial cells. We have identified the cardiovascular, renal, and hormonal responses that can be elicited in conscious dogs by intravenous administration of endothelin at rates of 10 and 30 ng . kg-l. min-' for 60 min (0.24 and 0.72 nmol. kg-'/lh infusion). Each dose of endothelin increased total peripheral resistance, arterial pressure, and left atria1 pressure and decreased heart rate and cardiac output. Hematocrit increased by 4.8% (NS) and 22.9% (P < 0.01) in response to the lower and higher infusion rates, respectively. Urinary sodium excretion, urine osmolality, and osmolar clearance decreased and free water clearance increased. The lower dose of endothelin decreased plasma norepinephrine and increased plasma atriopeptin. The higher dose increased plasma levels of vasopressin, renin, aldosterone, norepinephrine, epinephrine, and atriopeptin. The higher infusion rate of the peptide caused one or more brief vomiting episodes in four of five dogs. Although it is not yet known whether endothelin is a circulating hormone, it is clear that this peptide is capable of causing profound cardiovascular, renal, and endocrine alterations in conscious dogs. The possible relevance of these observations to physiological processes and to pathological conditions such as hypertension remains to be established. vascular endothelium; peptide hormone; baroreflex; vasopressin; renin; aldosterone; atriopeptin; atria1 natriuretic factor; epinephrine; norepinephrine ENDOTHELIN is a recently discovered &amino acid peptide that is capable of producing marked vasoconstriction (23). The endothelium of porcine aortic tissue contains mRNA encoding for preproendothelin, thus indicating that endothelin is synthesized in endothelial cells of blood vessels (23). A human preproendothelin cDNA has been cloned from a human placenta cDNA library (16); human preproendothelin has 212 amino acid residues, and it contains a 21-amino acid sequence that is identical to that of porcine endothelin. It is not yet known whether endothelin circulates in plasma, and the functional role of this peptide remains to be identified.
Interest in the role of the endothelium as a modulator of vascular responsiveness was stimulated by the innovative work of Furchgott and Zawadzki (8), who demonstrated that the vasodilation evoked by acetylcholine depends on the presence of endothelial cells. Acetylcholine acts on muscarinic receptors that cause endothelial cells to release a fact.or that relaxes blood vessels. This factor was named endothelium-derived relaxing factor by Furchgott (see Ref. 7 for review). Endothelium-derived relaxing factor possesses chemical and pharmacological characteristics that are identical to those of nitric oxide (15, 19).
Subsequent work indicated that the endothelium also contains a factor (or factors) that causes vasoconstriction (e.g., 17). This factor has been referred to as endothelium-derived contracting factor, and evidence suggested that at least one such contracting factor is a peptide (10, 14, 18). The discovery of endothelin (23) therefore extended the earlier work on endothelium-derived contracting factor.
Synthetic endothelin has recently become available. Our interest in the effects of peptides on cardiovascular, renal, and endocrine systems prompted us to investigate the effects of intravenously administered endothelin on these systems in conscious dogs.
METHODS
Surgical preparation. Five female mongrel dogs weighing 20.6 t 1.2 kg were surgically prepared as described previously (9). Briefly, catheters were placed in the descending aorta, right and left atria, and pulmonary artery; an ultrasonic transit-time flow probe (Transonic Systems, Ithaca, NY) was placed around the ascending aorta.
Experimental procedures. Dogs were fed a diet containing -45-50 meq of sodium/day. Experiments were performed on conscious dogs 2-4 wk after the surgical operation. A self-retaining catheter was inserted into the bladder, and the dog was placed in a Pavlov-type stand. After a 40-min control period, endothelin (Peptides International, Louisville, KY) was dissolved in isotonic saline and infused intravenously for 1 h at a rate of 10 or 30 ng l kg-'. min-' (0.19 ml/min); the infusion period was followed by a 40-min recovery period. Each dog received an infusion of endothelin on two separate days. Urine was collected at 2O-min intervals, and hemodynamic variables were monitored continuously, digitized at a sampling rate of 100 Hz, and analyzed by a PDP ll/ 34 computer (Digital Equipment, Maynard, MA) as de- 1. Hemodynamic effects of l-h infusions of endothelin at 10 and 30 ng= kg-'.min-' in five conscious dogs. AP, aortic pressure; LAP, left atria1 pressure; RAP, right atria1 pressure; PAP, pulmonary arterial pressure; HR, heart rate; SV, stroke volume; CO, cardiac output; TPR, total peripheral resistance. Cross-hatched bar represents period of infusion. Solid line represents data obtained in experiment employing an infusion of 10 ng. kg-'. min-', and dashed line represents data obtained in experiment employing an infusion of 30 ng= kg-'. min. * P < 0.05 compared with control value immediately preceding infusion. scribed previously (5). Ascending aortic blood flow was considered to represent cardiac output. Total peripheral resistance is reported in peripheral resistance units (PRU) calculated as [mean aortic pressure (mmHg) -mean right atria1 pressure (mmHg)]/cardiac output (ml/ s). Pulmonary vascular resistance was calculated by the formula, [mean pulmonary arterial pressure (mmHg) -mean left atria1 pressure (mmHg)]/cardiac output (ml/ s). Blood samples (23 ml) were taken 5 min before the end of the control, infusion, and recovery periods and at the midpoint of the infusion period. Blood samples were replaced with an equal volume of isoncotic dextran in isotonic saline. Plasma was separated by centrifugation, and osmolality and electrolytes were measured on aliquots of fresh plasma. The remaining plasma was stored at -70°C for subsequent analysis of vasopressin, atriopeptin, epinephrine, norepinephrine, aldosterone, and renin activity.
ChemicaZ analyses. Plasma concentrations of immunoreactive atriopeptin were determined by radioimmunoassay after extraction with Sep-Pak Cl8 cartridges (Waters Associates, Milford, MA) as described previously (9). Arginine vasopressin was extracted from plasma with Sep-Pak Cl8 cartridges and measured by radioimmunoassay as described by Goetz et al. (11) Statistical analyses. Cardiovascular variables from each experiment were averaged for consecutive 20.min periods. All data are expressed as means t SE. Data within each experiment were analyzed by a one-way analysis of variance for repeated measurements of the same variable. Dunnett's test was used to determine which means differed statistically from control means.
RESULTS
The infusion of endothelin produced multiple cardiovascular, renal, and endocrine changes in the conscious dog. The cardiovascular responses are summarized in Fig. 1 . Infusion of endothelin at 10 ng l kg-'. mine1 increased aortic pressure, left and right atria1 pressures, and total peripheral resistance; it also decreased heart rate and cardiac output. Infusion of endothelin at 30 ng l kg-'.min-' produced more striking changes in most cardiovascular variables, but heart rate changes were simi- Other abbreviations as in Fig. 1 . lar, right atria1 pressure did not increase, and stroke volume decreased significantly. Pulmonary arterial pressure was unchanged during each infusion (Fig. l) , but calculated pulmonary vascular resistance increased from 0.35 t 0.05 to 0.53 t 0.14 PRU (P < 0.05) in response to the higher infusion rate. Cardiovascular variables tended to return toward control values after the infusion of endothelin was stopped, although several remained significantly different from control values at the end of the experiment (Fig. 1) .
The effect of endothelin on renal function is illustrated in Fig. 2 . Infusion of the higher dose of endothelin decreased sodium excretion, potassium excretion, urine osmolality, and osmolar clearance, and increased free water clearance. Sodium excretion and osmolar clearance approached zero, and urine osmolality approached isotonicity. Qualitatively similar, but considerably less pronounced responses were observed during infusion of the lower dose of endothelin (Fig. 2) . Urine flow tended to increase in response to the lower infusion rate and decrease in response to the higher rate, but these trends were not statistically significant.
Hematocrit increased from 33.6 t 2.0 to 35.2 t 2.1 (+4.8%, NS) in response to the lower infusion rate and from 33.2 t 1.2 to 40.8 t 2.2 (+22.9%, P < 0.01) in response to the higher infusion rate (Table 1) . Hematocrit declined after the infusion ended. In another dog with its spleen removed, hematocrit did not increase in response to the higher dose of endothelin. Plasma sodium decreased slightly in response to the higher infusion rate; plasma potassium and plasma osmolality were unchanged during these experiments (Table 1) . The higher dose of endothelin caused significant increases in plasma levels of vasopressin, renin, aldosterone, norepinephrine, epinephrine, and atriopeptin.
In a pilot experiment, we had infused endothelin intravenously at a rate of 350 ng . kg-'. min? This infusion produced profound responses, and it was stopped within 10 min. Cardiac output decreased to ~20% of the control value, and the dog vomited and defecated. Because of these pilot data, we reduced the initial rate of infusion of endothelin in the present study to 10 ng . kg-'. min-', a rate that produced no gastrointestinal symptoms in any of the dogs. Infusion of endothelin at 30 ng l kg-'. min-', however, did produce one or two brief periods of vomiting in four of the five dogs. Most of the vomiting occurred late in the infusion period; specific times in the four individual dogs were 45, 12 and 50, 55, and 30 and 55 min after the infusion began. Because of the vomiting, a series of experiments with higher infusion rates was not attempted.
The pressor responses to the two doses of endothelin infused in this study were compared with pressor responses to l-h infusions of vasopressin and angiotensin II that were performed previously in this laboratory (21). The data are summarized in Table 2 . Each agent produced increases in blood pressure when given at rates of several picomoles per kilogram per minute. The maximal pressor response to endothelin was compared with the maximal response to vasopressin and also to angiotensin II by means of an unpaired t test. No significant differences in the maximal pressor responses were detected. The pressor response to 12 pmol. kg-'. min-' of endothelin (molecular weight of endothelin: 2,492) was essentially the same as that obtained with an infusion of vasopressin at 5 pmol . kg-'. min-'. DISCUSSION The administration of endothelin into conscious dogs demonstrated that this peptide is capable of producing marked effects on cardiovascular, renal, and endocrine function. Many of the cardiovascular changes evoked by the peptide appeared to be initiated by its effects on total peripheral resistance. The elevation of vascular resistance was responsible for the increase in arterial blood pressure that in turn elicited reflex decreases in heart rate and cardiac output via the arterial baroreceptors, although the peptide also conceivably could have exerted a direct effect on the heart. The increases in atria1 pressure presumably reflect the increase in ventricular afterload and reduction in cardiac output. At the higher infusion rate, however, right atria1 pressure did not increase.
The increase in hematocrit caused by endothelin administration probably was caused by an increase in circulating red cell mass induced by splenic contraction; no increase in hematocrit occurred when endothelin was given to a conscious splenectomized dog.
The infusion of endothelin profoundly altered renal function. The decreases in urinary sodium, potassium, and osmolar excretion, changes that were sizable at the higher infusion of endothelin, occurred when blood pressure was considerably elevated. It is likely that the vasoconstrictive action of endothelin caused a substantial decrease in glomerular filtration rate that in turn was responsible for the reduced excretion of electrolytes. The decrease in urine osmolality and increase in free water clearance occurred in the presence of an unchanged or increased concentration of vasopressin in plasma. Thus vasopressin was unable to cause the formation of a concentrated urine in this situation. This may be explained at least partly because atriopeptin, which increased significantly in these experiments, inhibits the action of vasopressin on renal collecting ducts perfused in vitro (4). In addition, the rise in vasopressin may have occurred relatively late in the endothelin infusion (the brief vomiting periods occurred largely near the end of the infusion) and thus may have had little time to influence renal function during the infusion. It also has been demonstrated that atriopeptin causes dehydrated human volunteers to produce hypotonic urine despite high circulating concentrations of vasopressin (1) . We attribute the rise in plasma atriopeptin in the present experiments to an increased secretion of atriopeptin elicited by the increase in atria1 pressure that occurred during infusion of endothelin.
Four of the five dogs demonstrated substantial increases in plasma vasopressin in response to the higher infusion rate of endothelin, and these were the same dogs that vomited during the infusion. The other dog, which did not vomit, did not increase its circulating vasopressin level during the infusion. Vomiting is known to be a potent stimulus for vasopressin secretion (20). It is likely therefore that vomiting was the stimulus responsible for the increase in plasma vasopressin during infusion of the higher dose of endothelin.
This stimulus was potent enough to overcome inhibitory influences on vasopressin The decline in circulating norepinephrine during infusion of the lower rate of endothelin probably reflected a decrease in sympathetic neural discharge to the heart and blood vessels that was mediated by a reflex from the arterial baroreceptors. However, plasma norepinephrine increased in response to the higher dose of endothelin, as did plasma epinephrine, which is derived from the adrenal medulla. It is likely therefore that the adrenal medulla was responsible for the rise in plasma catecholamines that occurred during infusion of the higher dose of endothelin. Release of catecholamines from the adrenal medulla is influenced relatively little by the arterial baroreceptors under most circumstances (6). Accordingly, the augmented secretion of catecholamines from the adrenal medulla may have been caused by an endothelin-mediated vasoconstriction that reduced blood flow to that tissue and produced an acidosis, a stimulus known to evoke the secretion of catecholamines (2) .
The significant increase in plasma renin activity caused by the higher infusion rate of endothelin may have been caused by vasoconstriction of the renal vessels proximal to the juxtaglomerular ceils, by a reduction in the amount of sodium reaching the macula densa, or by the increase in circulating catecholamines (3). Changes in plasma aldosterone followed the changes in plasma renin activity and may have been caused by them.
Although endothelin appears to be more potent than other constrictor peptides in vitro (23), the data from experiments in the conscious dog (Table 2) indicate that the effectiveness of endothelin as a pressor agent is approximately equal to that of vasopressin and angiotensin II. On a molar basis, vasopressin appeared to be slightly more potent than endothelin as a pressor agent in the conscious dog.
It is not yet known whether endothelin is a circulating hormone. It may simply act at a local level. The data presented here indicate that endothelin possesses pressor activity similar to that of angiotensin II and vasopressin. Moreover, endothelin, like vasopressin and angiotensin, is capable of influencing the kidneys and several endocrine organs. Consequently, if endothelin does circulate in plasma, it conceivably could serve as a modulator of a number of cardiovascular, renal, and endocrine processes.
